Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 20, 2023

Clinical Impact of Ibrutinib Plus R-CHOP in Patients With Untreated DLBCL With BCL2 and MYC Co-Expression

Blood Advances


Additional Info

Disclosure statements are available on the authors' profiles:

Blood Advances
Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL co-expressing BCL2 and MYC in the phase 3 PHOENIX trial
Blood Adv 2023 Jan 25;[EPub Ahead of Print], PWM Johnson, S Balasubramanian, B Hodkinson, SM Shreeve, S Sun, S Srinivasan, AJ Steele, J Vermeulen, LH Sehn, WH Wilson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading